Neurosense Therapeutics Ltd Stock Performance
| NRSNW Stock | USD 0.34 0.00 0.00% |
NeuroSense Therapeutics holds a performance score of 5 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of -0.57, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning NeuroSense Therapeutics are expected to decrease at a much lower rate. During the bear market, NeuroSense Therapeutics is likely to outperform the market. Use NeuroSense Therapeutics sortino ratio, semi variance, as well as the relationship between the Semi Variance and day typical price , to analyze future returns on NeuroSense Therapeutics.
Risk-Adjusted Performance
Mild
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in NeuroSense Therapeutics Ltd are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady basic indicators, NeuroSense Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 2.6 M | |
| Total Cashflows From Investing Activities | 1000.00 |
NeuroSense | Build AI portfolio with NeuroSense Stock |
NeuroSense Therapeutics Relative Risk vs. Return Landscape
If you would invest 37.00 in NeuroSense Therapeutics Ltd on October 28, 2025 and sell it today you would lose (3.00) from holding NeuroSense Therapeutics Ltd or give up 8.11% of portfolio value over 90 days. NeuroSense Therapeutics Ltd is currently producing 1.4551% returns and takes up 20.4992% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than NeuroSense, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
NeuroSense Therapeutics Target Price Odds to finish over Current Price
The tendency of NeuroSense Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.34 | 90 days | 0.34 | about 74.75 |
Based on a normal probability distribution, the odds of NeuroSense Therapeutics to move above the current price in 90 days from now is about 74.75 (This NeuroSense Therapeutics Ltd probability density function shows the probability of NeuroSense Stock to fall within a particular range of prices over 90 days) .
Assuming the 90 days horizon NeuroSense Therapeutics Ltd has a beta of -0.57. This indicates as returns on the benchmark increase, returns on holding NeuroSense Therapeutics are expected to decrease at a much lower rate. During a bear market, however, NeuroSense Therapeutics Ltd is likely to outperform the market. Additionally NeuroSense Therapeutics Ltd has an alpha of 0.5682, implying that it can generate a 0.57 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). NeuroSense Therapeutics Price Density |
| Price |
Predictive Modules for NeuroSense Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as NeuroSense Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.NeuroSense Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. NeuroSense Therapeutics is not an exception. The market had few large corrections towards the NeuroSense Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold NeuroSense Therapeutics Ltd, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of NeuroSense Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.57 | |
β | Beta against Dow Jones | -0.57 | |
σ | Overall volatility | 0.12 | |
Ir | Information ratio | 0.02 |
NeuroSense Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of NeuroSense Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for NeuroSense Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| NeuroSense Therapeutics is not yet fully synchronised with the market data | |
| NeuroSense Therapeutics is way too risky over 90 days horizon | |
| NeuroSense Therapeutics has some characteristics of a very speculative penny stock | |
| NeuroSense Therapeutics appears to be risky and price may revert if volatility continues | |
| NeuroSense Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (10.21 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| NeuroSense Therapeutics Ltd has accumulated about 994 K in cash with (10.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.13. | |
| NeuroSense Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Loss-Making Acurx Pharmaceuticals, Inc. Expected To Breakeven In The Medium-Term |
NeuroSense Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of NeuroSense Stock often depends not only on the future outlook of the current and potential NeuroSense Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. NeuroSense Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 18.6 M | |
| Cash And Short Term Investments | 3.4 M |
NeuroSense Therapeutics Fundamentals Growth
NeuroSense Stock prices reflect investors' perceptions of the future prospects and financial health of NeuroSense Therapeutics, and NeuroSense Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on NeuroSense Stock performance.
| Return On Equity | -24.78 | ||||
| Return On Asset | -3.04 | ||||
| EBITDA | (9.88 M) | ||||
| Net Income | (10.21 M) | ||||
| Cash And Equivalents | 994 K | ||||
| Cash Per Share | 0.13 X | ||||
| Total Debt | 73 K | ||||
| Current Ratio | 8.08 X | ||||
| Book Value Per Share | (0.02) X | ||||
| Cash Flow From Operations | (10.13 M) | ||||
| Earnings Per Share | (0.94) X | ||||
| Total Asset | 4.58 M | ||||
| Retained Earnings | (36.66 M) | ||||
| Working Capital | 2.41 M | ||||
About NeuroSense Therapeutics Performance
Evaluating NeuroSense Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if NeuroSense Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if NeuroSense Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -13.6 K | -14.3 K | |
| Return On Tangible Assets | (2.57) | (2.69) | |
| Return On Capital Employed | (3.45) | (3.28) | |
| Return On Assets | (2.57) | (2.69) | |
| Return On Equity | (3.56) | (3.38) |
Things to note about NeuroSense Therapeutics performance evaluation
Checking the ongoing alerts about NeuroSense Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for NeuroSense Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| NeuroSense Therapeutics is not yet fully synchronised with the market data | |
| NeuroSense Therapeutics is way too risky over 90 days horizon | |
| NeuroSense Therapeutics has some characteristics of a very speculative penny stock | |
| NeuroSense Therapeutics appears to be risky and price may revert if volatility continues | |
| NeuroSense Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (10.21 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| NeuroSense Therapeutics Ltd has accumulated about 994 K in cash with (10.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.13. | |
| NeuroSense Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Loss-Making Acurx Pharmaceuticals, Inc. Expected To Breakeven In The Medium-Term |
- Analyzing NeuroSense Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether NeuroSense Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining NeuroSense Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating NeuroSense Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of NeuroSense Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of NeuroSense Therapeutics' stock. These opinions can provide insight into NeuroSense Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for NeuroSense Stock Analysis
When running NeuroSense Therapeutics' price analysis, check to measure NeuroSense Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuroSense Therapeutics is operating at the current time. Most of NeuroSense Therapeutics' value examination focuses on studying past and present price action to predict the probability of NeuroSense Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuroSense Therapeutics' price. Additionally, you may evaluate how the addition of NeuroSense Therapeutics to your portfolios can decrease your overall portfolio volatility.